AARTIPHARM.NSAARTIPHARM.NSNSE

Revenue (LTM)

$21.2B

+16.5% YoY

Net Income (LTM)

$2.7B

+25.6% YoY

Free Cash Flow

$-705M

Revenue CAGR (5Y)

—

Marginsimproving

FCFTurned negative

Profitable

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Revenue	0	11,920	19,452↑63.2%	18,155↓6.7%	21,151↑16.5%
Gross Profit	0	3,123	4,139↑32.5%	3,908↓5.6%	9,872↑152.6%
Operating Income	-0	1,648↑3586388.1%	2,795↑69.6%	2,815↑0.7%	3,775↑34.1%
Net Income	-0	1,223↑2660045.6%	1,935↑58.3%	2,169↑12.1%	2,724↑25.6%
EBITDA	-0	1,978↑4304693.1%	3,444↑74.1%	3,909↑13.5%	4,745↑21.4%
EPS Diluted	-0.18	13.49↑7594.4%	21.35↑58.3%	23.93↑12.1%	30.04↑25.5%

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Cash & Equivalents	3	833↑33209.4%	121↓85.4%	236↑95.0%	86↓63.4%
Total Current Assets	3	10,281↑411159.0%	11,630↑13.1%	13,456↑15.7%	13,222↓1.7%
Total Assets	3	20,399↑815859.8%	22,440↑10.0%	25,821↑15.1%	29,064↑12.6%
Total Current Liabilities	0	5,807↑2651337.9%	6,006↑3.4%	6,944↑15.6%	6,570↓5.4%
Total Liabilities	0	6,534↑2807768.1%	6,855↑4.9%	8,251↑20.4%	9,165↑11.1%
Total Equity	2	13,865↑611413.5%	15,585↑12.4%	17,570↑12.7%	19,899↑13.3%
Total Debt	0	3,414↑1973313.3%	2,153↓36.9%	2,853↑32.5%	4,131↑44.8%
Net Debt	-2	2,581↑111027.0%	2,032↓21.3%	2,616↑28.8%	4,045↑54.6%

Metric	Mar 22	Mar 23	Mar 24	Mar 25
Operating Cash Flow	-437	2,501↑672.3%	2,164↓13.5%	3,316↑53.2%
Capital Expenditure	-1,412	-1,197↑15.2%	-1,988↓66.1%	-4,020↓102.2%
Free Cash Flow	-1,849	1,305↑170.6%	176↓86.5%	-705↓501.1%
Stock-Based Comp	0	0	2	0
Net Change in Cash	830	-712↓185.7%	115↑116.2%	-169↓246.8%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance